Find A PAL
Connect With Your Pfizer Patient Affairs Liaison
The Pfizer Patient Affairs Liaisons (PALs) help connect patients living with a rare disease to educational resources. Pfizer PALs are field-based employees of Pfizer and, if you choose, will provide you with educational resources for awareness and management of your rare disease. Some of the ways a PAL can help patients and their caregivers include:
- Connect with advocacy groups that can provide resources and support
- Provide educational resources about living with a rare disease
- Supply helpful information and answer questions about Pfizer programs and resources
Pfizer PALs are not able to provide medical advice. Questions about treatment and management of a rare disease should be discussed with your health care provider. Pfizer PALs do not share personal or contact information in order to promote Pfizer products and do not contact patients or caregivers without their consent. Even if you choose not to opt-in for Pfizer PAL support, you may still access all other Pfizer patient support offerings for which you are eligible.
By completing and submitting the form below, I am providing my health information to Pfizer and requesting Pfizer PAL support. I agree that the Pfizer PAL assigned to my case may contact me by telephone using an autodialer at the telephone number(s) provided below, or by video and/or email, based on my preferred means of communication, regarding patient/caregiver educational programs, resources and other information relevant to my awareness and management of the therapeutic area that I have selected below.
Pfizer may email me with educational information for the selected rare disease and educational information relevant to living with a rare disease generally. I understand that my consent for PAL support is optional and is not required in order to purchase any Pfizer products or services. I understand that I (and, if applicable, my caregiver) can opt-out of these communications at any time by contacting my assigned Pfizer PAL or by clicking here.